Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine

García‐Grimshaw, Miguel; Michel-Chávez, Anaclara; Vera-Zertuche, Juan Mauricio; Galnares-Olalde, Javier Andrés; Hernández-Vanegas, Laura E.; Figueroa-Cucurachi, Melissa; Paredes-Ceballos, Orlando; Reyes‐Terán, Gustavo; Carbajal-Sandoval, Guillermo; Ceballos‐Liceaga, Santa Elizabeth; Araúz, Antonio; Valdés‐Ferrer, Sergio Iván

doi:10.1016/j.clim.2021.108818

Cited by 74 publications

(85 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only five patients (38.4%) reported a previous infection before GBS-related symptoms, comparable with a recent report ( García-Grimshaw et al, 2021 ). AIDP was the most common electrophysiological variant encountered in this population, opposite to previous Mexican epidemiological reports, where axonal variants were more common in Mexican children (59% and 87.5%) ( Jackson et al, 2014 , Larrosa-Haro et al, 2010 ).…”

Section: Discussionsupporting

confidence: 91%

“…Moreover, COVID-19 vaccines and GBS reports are scarce, with no apparent association ( Trimboli et al, 2021 ). However, another Mexican national health institute has reported seven GBS cases after 3,890,250 people received at least one dose of BNT162b2Mrna (Pfizer) at the beginning of 2021, representing a low incidence of 0.18 per 100,000 vaccinated persons ( García-Grimshaw et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Guillain-Barré syndrome following SARS-CoV-2 vaccination: Is there a real association?

López-Hernández

Bazán-Rodríguez

Adib

et al. 2022

Neuroimmunology Reports

View full text Add to dashboard Cite

Background Guillain-Barre Syndrome (GBS) is the most common cause of acute flaccid paralysis, with an incidence of 0.81-1.89 cases per 100,000. With the SARS-CoV-2 virus pandemic, major international vaccination campaigns continue to be carried out to minimize the total burden of the disease. This study aims to report a case series of consecutive GBS patients after SARS-CoV-2 vaccination during the massive campaign in Mexico in 2021. Methods A single-center, observational study of consecutive GBS subjects diagnosed by Asbury criteria from January 1 to August 31, 2021. Including GBS-related symptoms on or after six weeks of vaccination record, both first and second doses. Results From a total of 53 GBS patients, eight had a history of SARS-CoV-2 vaccination, 87.5% male, the median vaccination-symptom onset and symptom-to-admission time were 15 (IQR 12.75-23.25), and 3.5 (IQR 1.5-8.25), all of them had GBS Disability Scale ≥3 at admission. Acute inflammatory demyelinating polyneuropathy (AIDP) was the most common electrophysiological variant encountered in this population. All patients received treatment Intravenous Immunoglobulin (IVIG) or Plasma Exchange (PE), 62.5% recovered independent walk at three months follow up. Conclusion The annual incidence of GBS cases associated with vaccination remains lower (0.81 - 1.89 cases / 100,000 persons) than non-vaccinated patients; this should encourage health authorities to continue promoting massive vaccination as benefits outweigh the risks.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Guillain-Barré syndrome following SARS-CoV-2 vaccination: Is there a real association?

López-Hernández

Bazán-Rodríguez

Adib

et al. 2022

Neuroimmunology Reports

View full text Add to dashboard Cite

show abstract

“…Despite the study limitations, the absolute risk of GBS following this vaccination seems to be extremely small and much lower than the risk of COVID-19 infection [77]. The research conducted in Mexico [78] showed that GBS is infrequent among recipients of the BNT162b2 vaccine (Pfizer-BioNTech). The most cases of GBS emergence after vaccination were related to concomitant factors identified as gastrointestinal infections.…”

Section: Discussionmentioning

confidence: 93%

Facial Diplegia—Complication or Manifestation of SARS-CoV-2 Infection? A Case Report and Systemic Literature Review

et al. 2021

View full text Add to dashboard Cite

Since the outbreak of the new coronavirus, healthcare systems around the world have witnessed not only COVID-19 symptoms but also long-term complications of the aforementioned, including neurological problems. We report a clinical case of an adult patient with bilateral facial nerve palsy and progressive ascending paresis of the limbs after contracting the novel coronavirus (COVID-19). Additionally, the systematic review aimed to identify and summarize specific clinical features, outcomes and complications of the studies focusing on bilateral facial diplegia as a sequela of COVID-19 infection. The total number of analyzed patients was 15. Only one patient was diagnosed with isolated bilateral palsy; the rest had Guillain-Barré Syndrome (GBS). With one exception, all the presented cases had favorable outcomes, with facial palsy recovery from slight to almost complete. In patients with a confirmed COVID-19 diagnosis, bilateral facial palsy may be an isolated symptom as well as a variant of GBS. Symptoms of cranial nerve damage during a COVID-19 infection may explain the appearance of facial nerve damage. In order to clarify the spectrum of neurological manifestations and a causal relation between SARS-CoV-2, COVID-19 vaccination and neurological symptoms, direct attention towards the study of this virus is crucial. It seems reasonable to recognize human coronavirus as another potential GBS trigger.

show abstract

“…A smaller proportion of cases are also associated with surgery, trauma, and vaccinations [1][2][3]. Recently, cases of GBS have been reported after vaccination against coronavirus disease 2019 (COVID-19) [4][5][6][7][8][9][10]. We are reporting the first known case of Guillain-Barré syndrome with sub-acute onset that occurred after receiving the first dose of an mRNA-1273 vaccine.…”

Section: Introductionmentioning

confidence: 99%

Sub-acute Onset of Guillain-Barré Syndrome Post-mRNA-1273 Vaccination: a Case Report

Nagalli

Kikkeri

2022

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Ever since the start of the pandemic, SARS-CoV-2 has taken the lives of millions of people around the globe. Several COVID-19 vaccines have been developed with rapidity to prevent acquiring COVID-19 infection, hospitalizations, and deaths. The routine side effects of these vaccines are commonly known and non-severe. Few serious side effects such as thrombosis with thrombocytopenia syndrome (TTS) and Guillain-Barré syndrome (GBS) are increasingly reported particularly after inoculation with ChAdOx1 nCoV-19 (Oxford/AstraZeneca) and Ad26.COV 2.S (Johnson & Johnson’s Janssen). Rare cases of GBS after BNT162b2 (Pfizer-BioNTech), an mRNA vaccine, are also reported. However, the true association of these cases to COVID-19 continues to be unclear and the safety of these vaccines continues to be great in preventing deaths from COVID-19 infection. We report a case of middle-aged female who had a gradual onset of lower extremity weakness with a nadir of symptoms reached 10 and 12 weeks after the onset. This protracted course (sub-acute) is atypical for a “classical” GBS. The presence of an antecedent event, autonomic symptoms such as hypotension, and the need for ventilator support favored the diagnosis of GBS than chronic inflammatory demyelinating polyneuropathy (CIDP). This is the first known case to be reported of sub-acute onset of Guillain-Barré syndrome after receiving the mRNA-1273 vaccine. Supplementary Information The online version contains supplementary material available at 10.1007/s42399-022-01124-1.

show abstract

Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine

Cited by 74 publications

References 20 publications

Guillain-Barré syndrome following SARS-CoV-2 vaccination: Is there a real association?

Guillain-Barré syndrome following SARS-CoV-2 vaccination: Is there a real association?

Facial Diplegia—Complication or Manifestation of SARS-CoV-2 Infection? A Case Report and Systemic Literature Review

Sub-acute Onset of Guillain-Barré Syndrome Post-mRNA-1273 Vaccination: a Case Report

Contact Info

Product

Resources

About